Multiple casino-resorts in Primm, along with two gas stations and the Lotto Store, are set to permanently close, according to the company. For a town once built on constant traffic, bright lights and a steady stream of visitors heading in from California, the announcement feels like the end of an era.

Multiple casino-resorts in Primm, along with two gas stations and the Lotto Store, are set to permanently close, according to the company. For a town once built on constant traffic, bright lights and a steady stream of visitors heading in from California, the announcement feels like the end of an era.

High gas prices, fuel prices and news of budget airline Spirit shutting down operations is hitting people across the country and here in our valley.

Dr Jeffrey Cummings, of the University of Nevada, Las Vegas, has published an annual review of clinical trials for Alzheimer’s drugs for the past decade. The latest review, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, reveals a shifting approach to the disease, with fewer drugs designed to remove amyloid and more targeting tau, inflammation and other immune system pathways.

A major donation drew attention after the Lombardo admin’s firing of the state water engineer, whom the industry had complained about.

Manoj Sharma, a tenured professor of social and behavioral health at the University of Nevada, Las Vegas, told The Epoch Times that a constantly busy schedule keeps the brain in a state of high alert, resulting in rapid beta waves visible on an electroencephalogram (EEG). This chronic overactivation depletes energy, leading to stress, burnout, mental fatigue, poor sleep, decreased work efficiency, and emotional neglect.

Every year, world‑leading dementia researcher Dr Jeffrey Cummings releases a global snapshot of Alzheimer’s trials – and the 2026 update has just been published. Right now, researchers are evaluating 158 medicines across 192 trials – marking an impressive 40% rise over the past decade. This year’s review also shows the most diverse Alzheimer’s drug pipeline to date.

The global effort to find a cure for Alzheimer’s disease has seen a 35% increase in the number of clinical trials and a 40% increase in therapies being tested since 2016, according to a new report from a UNLV researcher.